Pretransplantation pharmacokinetic curves of tacrolimus in HIV-infected patients on ritonavir-containing cART: A pilot study

Transplantation

Volumn 95, Issue 2, 2013, Pages 397-402

  Van Maarseveen, Erik M ^a   Crommelin, Heleen A ^a   Mudrikova, Tania ^a   Van Den Broek, Marcel P H ^a   Van Zuilen, Arjan D ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Dose modification; HIV; Immunosuppressant; Kidney transplantation; Pharmacokinetics; Ritonavir; Tacrolimus.

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DARUNAVIR; DIDANOSINE; EFAVIRENZ; ETRAVIRINE; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; RALTEGRAVIR; RITONAVIR; TACROLIMUS; TENOFOVIR; ZIDOVUDINE;

ADULT; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DISTRIBUTION VOLUME; DOSE CALCULATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG LAG TIME; DRUG RATE CONSTANT; DRUG WITHDRAWAL; FEMALE; GRAFT REJECTION; HIV ASSOCIATED NEPHROPATHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LEUKOPENIA; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM PLASMA CONCENTRATION; NEUROTOXICITY; PHARMACOLOGICAL PARAMETERS; PILOT STUDY; PLASMA CONCENTRATION-TIME CURVE; POSTOPERATIVE PERIOD; PREDICTIVE VALUE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RATE CONSTANT FROM THE CENTRAL TO THE PERIPHERAL COMPARTMENT; RATE CONSTANT FROM THE PERIPHERAL TO THE CENTRAL COMPARTMENT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION;

ADULT; AIDS-ASSOCIATED NEPHROPATHY; AREA UNDER CURVE; BIOTRANSFORMATION; COMPUTER SIMULATION; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; DRUG MONITORING; ENZYME INHIBITORS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PILOT PROJECTS; RITONAVIR; TACROLIMUS;

EID: 84872968770     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182734651     Document Type: Article

References (24)

1. Fine DM, Perazella MA, Lucas GM, et al. Renal disease in patients with HIV infection: epidemiology, pathogenesis and management. Drugs 2008; 68: 963.
2. Trullas JC, Cofan F, Tuset M, et al. Renal transplantation in HIVinfected patients: 2010 update. Kidney Int 2011; 79: 825.
3. Stock PG, Barin B, Murphy B, et al. Outcome of kidney transplantation in HIV-infected recipients. N Eng J Med 2010; 363: 2004.
4. Roland ME, Barin B, Carlson L, et al. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplant 2008; 8: 355.
5. Touzot M, Pillebout E, Matignon M, et al. Renal transplantation in HIV-infected patients: the Paris experience. Am J Transplant 2010; 10: 2263.
6. Kumar MS, Sierka DR, Damask AM, et al. Safety and success of kidney transplantation and concomitant immunosuppression in HIV-positive patients. Kidney Int 2005; 67: 1622.
7. Pirsch JD, Miller J, Deierhoi MH, et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK 506 Kidney Transplant Study Group. Transplantation 1998; 63: 977.
8. Venkataramanan R, Swaminathan A, Prasad T, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 1995; 29: 404.
9. Scholten EM, Cremers SCLM, Shoemaker RC, et al. AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients. Kidney Int 2005; 67: 2440.
10. Lemajieu WP, Maes BD, Verbeke K, et al. CYP3A4 and P-glycoprotein activity in healthy controls and transplant patients on cyclosporine vs tacrolimus vs sirolimus. Am J Transplant 2004; 4: 1514.
11. Lampen A, Christians U, Guengerich FP, et al. Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. Drug Metab Dispos 1995; 23: 1315.
12. van Maarseveen EM, Rogers CC, Trofe-Clarck JJ, et al. Drug-drug Interactions between antiretroviral and immunosuppressive drugs: a Review. accepted by AIDS:PC&STDs. 2012.
13. Frassetto LA, Browne M, Cheng A, et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant 2007; 7: 2816.
14. Jain AB, Venkataramanan R, Eghtesad B, et al. Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplant patients. Liver Transpl 2003; 9: 954.
15. Cousins D, Topping K, Lee V, et al. Successful tacrolimus treatment following renal transplant in a HIV-infected patient with raltegravir previously treated with a protease inhibitor based regimen. Drug Metabol Drug Interact 2011; 26: 139.
16. Morelle J, Goffin E, Wallemacq P, et al. Extended release tacrolimus and antiretroviral therapy in a renal transplant recipient: so extended! Transpl Int 2010; 23: 1065.
17. Neff GW, Bonham A, Tzakis AG, et al. Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. Liver Transpl 2003; 9: 239.
18. Sheikh AM, Wolf DC, Lebovics E, et al. Concomitant human immunodeficiency virus protease inhibitor therapy markedly reduces tacrolimus metabolism and increases blood levels. Transplantation 1999; 68: 307.
19. Tan HP, Kaczorowski DJ, Basu A, et al. Living-related donor renal transplantation in HIV+ recipients using alemtuzumab preconditioning and steroid-free tacrolimus monotherapy: a single center preliminary experience. Transplantation 2004; 78: 1683.
20. Bickel M, Anadol E, Vogel M, et al.Daily dosing of tacrolimus in patients treated with HIV-1 therapy containing a ritonavir-boosted protease inhibitor or raltegravir. J Antimicrob Chemother 2010; 65: 999.
21. Kageyama M, Namiki H, Fukushima H, et al. Effect of chronic administration of ritonavir on function of cytochrome P450 3A and P-glycoprotein in rats. Biol Pharm Bull 2005; 28: 130.
22. Katzenmaier S, Markert C, Riedel KD, et al. Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using a limited sampling strategy. Clin Pharmacol Ther 2011; 90: 666.
23. Tricot L, Teicher E, Peytavin G, et al. Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs. Am J Transplant 2009; 9: 1946.
24. Koolen SL, Oostendorp RL, Beijnen JH, et al. Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer. Br J Clin Pharmacol 2010; 69: 465.